Full Text View
Tabular View
Study Results
Related Studies
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
This study has been completed.

First Received on February 7, 2003.   Last Updated on February 17, 2011   History of Changes
Sponsor: Boehringer Ingelheim Pharmaceuticals
Information provided by: Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00054717
  Purpose

Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.


Condition Intervention Phase
HIV Infections
 Drug: Tipranavir
Drug: Ritonavir(r)
Drug: Comparitor Protease Inhibitor (CPI)
 Phase III

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency
MedlinePlus related topics: HIV/AIDS
Drug Information available for: Ritonavir Tipranavir
U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:
  • Treatment Response at Week 48 [ Time Frame: At week 48 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Time to Treatment Failure Through 48 Weeks of Treatment [ Time Frame: Week 48 ]
    Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements <1 log10 below baseline.


Secondary Outcome Measures:
  • Treatment Response at Week 24 [ Time Frame: Week 24 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 2 [ Time Frame: week 2 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 4 [ Time Frame: week 4 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 8 [ Time Frame: week 8 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 16 [ Time Frame: week 16 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 24 [ Time Frame: week 24 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 32 [ Time Frame: Week 32 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 40 [ Time Frame: Week 40 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 48 [ Time Frame: Week 48 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 56 [ Time Frame: week 56 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 64 [ Time Frame: week 64 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 72 [ Time Frame: Week 72 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 80 [ Time Frame: Week 80 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 88 [ Time Frame: Week 88 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Treatment Response at Week 96 [ Time Frame: Week 96 ]
    Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound

  • Time to Treatment Failure Through 96 Weeks of Treatment [ Time Frame: Week 96 ]
    time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements <1 log10 below baseline.

  • Time to Confirmed Virologic Failure Through 48 Weeks of Treatment [ Time Frame: Week 48 ]
    Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.

  • Time to Confirmed Virologic Failure Through 96 Weeks of Treatment [ Time Frame: Week 96 ]
    Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.

  • Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
    Viral Load (VL) >= 1 log reduction from baseline

  • Virologic Response at Week 2 [ Time Frame: Week 2 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 4 [ Time Frame: Week 4 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 8 [ Time Frame: Week 8 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 16 [ Time Frame: Week 16 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 24 [ Time Frame: Week 24 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 32 [ Time Frame: Week 32 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 40 [ Time Frame: Week 40 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 48 [ Time Frame: Week 48 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 56 [ Time Frame: Week 56 ]
    VL >= 1 log reduction from baseline

  • Virologic Response at Week 64 [ Time Frame: Week 64 ]
    VL >= 1 log reduction from baseline

  • Median Change From Baseline in Viral Load to Week 2 [ Time Frame: Baseline to Week 2 ]
  • Median Change From Baseline in Viral Load to Week 4 [ Time Frame: Baseline to Week 4 ]
  • Median Change From Baseline in Viral Load to Week 8 [ Time Frame: Baseline to Week 8 ]
  • Median Change From Baseline in Viral Load to Week 16 [ Time Frame: Baseline to Week 16 ]
  • Median Change From Baseline in Viral Load to Week 24 [ Time Frame: Baseline to Week 24 ]
  • Median Change From Baseline in Viral Load to Week 32 [ Time Frame: Baseline to Week 32 ]
  • Median Change From Baseline in Viral Load to Week 40 [ Time Frame: Baseline to Week 40 ]
  • Median Change From Baseline in Viral Load to Week 48 [ Time Frame: Baseline to Week 48 ]
  • Median Change From Baseline in Viral Load to Week 56 [ Time Frame: Baseline to Week 56 ]
  • Median Change From Baseline in Viral Load to Week 64 [ Time Frame: Baseline to Week 64 ]
  • Median Change From Baseline in Viral Load to Week 72 [ Time Frame: Baseline to Week 72 ]
  • Median Change From Baseline in Viral Load to Week 80 [ Time Frame: Baseline to Week 80 ]
  • Median Change From Baseline in Viral Load to Week 88 [ Time Frame: Baseline to Week 88 ]
  • Median Change From Baseline in Viral Load to Week 96 [ Time Frame: Baseline to Week 96 ]
  • Mean Change From Baseline to Week 2 in CD4+ Cell Count [ Time Frame: Baseline to Week 2 ]
  • Mean Change From Baseline to Week 4 in CD4+ Cell Count [ Time Frame: Baseline to Week 4 ]
  • Mean Change From Baseline to Week 16 in CD4+ Cell Count [ Time Frame: Baseline to Week 16 ]
  • Mean Change From Baseline to Week 24 in CD4+ Cell Count [ Time Frame: Baseline to Week 24 ]
  • Mean Change From Baseline to Week 32 in CD4+ Cell Count [ Time Frame: Baseline to Week 32 ]
  • Mean Change From Baseline to Week 40 in CD4+ Cell Count [ Time Frame: Baseline to Week 40 ]
  • Mean Change From Baseline to Week 48 in CD4+ Cell Count [ Time Frame: Baseline to Week 48 ]
  • Mean Change From Baseline to Week 56 in CD4+ Cell Count [ Time Frame: Baseline to Week 56 ]
  • Mean Change From Baseline to Week 64 in CD4+ Cell Count [ Time Frame: Baseline to Week 64 ]
  • Mean Change From Baseline to Week 72 in CD4+ Cell Count [ Time Frame: Baseline to Week 72 ]
  • Mean Change From Baseline to Week 80 in CD4+ Cell Count [ Time Frame: Baseline to Week 80 ]
  • Mean Change From Baseline to Week 88 in CD4+ Cell Count [ Time Frame: Baseline to Week 88 ]
  • Mean Change From Baseline to Week 96 in CD4+ Cell Count [ Time Frame: Baseline to Week 96 ]
  • Time to New CDC Class C Progression Event or Death. [ Time Frame: after 48 weeks of treatment ]
    23 patients in the TPV/r group and 16 patients in the CPI/r group.

  • Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 2 [ Time Frame: Week 2 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 4 [ Time Frame: Week 4 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 8 [ Time Frame: Week 8 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 16 [ Time Frame: Week 16 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 24 [ Time Frame: Week 24 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 32 [ Time Frame: week 32 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 40 [ Time Frame: Week 40 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 48 [ Time Frame: Week 48 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 56 [ Time Frame: Week 56 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 64 [ Time Frame: Week 64 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 72 [ Time Frame: Week 72 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 80 [ Time Frame: Week 80 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 88 [ Time Frame: week 88 ]
    Viral Load < 400 copies/mL

  • Virologic Response at Week 96 [ Time Frame: week 96 ]
    Viral Load < 400 copies/mL

  • Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 2 [ Time Frame: Week 2 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 4 [ Time Frame: Week 4 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 8 [ Time Frame: Week 8 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 16 [ Time Frame: Week 16 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 24 [ Time Frame: Week 24 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 32 [ Time Frame: Week 32 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 40 [ Time Frame: Week 40 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 48 [ Time Frame: Week 48 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 56 [ Time Frame: Week 56 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 64 [ Time Frame: Week 64 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 72 [ Time Frame: Week 72 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 80 [ Time Frame: Week 80 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 88 [ Time Frame: Week 88 ]
    Viral Load < 50 copies/mL

  • Virologic Response at Week 96 [ Time Frame: Week 96 ]
    Viral Load < 50 copies/mL


Enrollment: 630
Study Start Date: January 2003
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Tipranavir(TPV)/low dose ritonavir(r) Drug: Tipranavir Drug: Ritonavir(r)
Comparitor protease inhibitor(CPI)/low dose ritonavir(r) Drug: Ritonavir(r) Drug: Comparitor Protease Inhibitor (CPI)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients meeting the following criteria will be eligible for participation in th is study:

  1. Human Immunodeficiency virus 1 (HIV-1) infected males or females >=18 years of age.
  2. Screening genotypic resistance report indicating both of the following: at least one primary protease Inhibitor (PI) mutation at the following sites:

30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on codons 33, 82, 84, or 90.

3. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV) medication regimen for at least 3 months prior to randomization.

4. Human Immunodeficiency Virus 1 (HIV-1) viral load >=1,000 copies/mL at screening.

Exclusion criteria:

Patients with any of the following criteria are excluded from participation in t he study:

  1. Antiretroviral (ARV) medication naïve.
  2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the last 3 months.
  3. alanine aminotransferase (ALT) >=3.0x upperlimit of normal (ULN) and aspartate aminotransferase(AST) >=2.5x upper limit of normal (ULN) (>=Division of AIDS(DAIDS) Grade 1) at either screening visit.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00054717

  Show 117 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site
Related Info  This link exits the ClinicalTrials.gov site

No publications provided by Boehringer Ingelheim Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5;368(9534):466-75.

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00054717     History of Changes
Other Study ID Numbers: 1182.12
Study First Received: February 7, 2003
Results First Received: September 9, 2009
Last Updated: February 17, 2011
Health Authority: Australia: Responsilble Ethics Committee;   Canada: Health Canada (TPD);   United States: Food and Drug Administration

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Protease Inhibitors
 Ritonavir
Tipranavir
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
HIV Protease Inhibitors
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 12, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services